BIOMAT Database Logo BIOMAT Database Logo

Specific activity of concentrated and purified cell culture rabies vaccine (CPCRV) from the strain Vnukovo -32-107 in an experiment with therapeutical immunization of humans. 1982

M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva

Reactogenicity and specific activity of three series of concentrated and purified cell culture rabies vaccine (CPCRV) were studied in an experiment of therapeutical immunization of 300 human subjects bitten by domestic animals, category "C". CPCRV was well tolerated; when administered intramuscularly, it did not provoke local reactions, while general reactions, such as temporary headaches and indisposition, were observed in 4% of cases. Intradermal revaccination with CPCRV was followed by local reactions in 73.6% of cases. Such a reaction can be regarded as a cutaneous allergic test. Coded paired sera of 263 subjects were examined in the neutralization reaction on mice. After primary intramuscular immunization, antibody titres were found to be very low. Relatively high titres of antibodies and 100% seroconversion were recorded after a single intramuscular or intradermal revaccination with CPCRV. Relatively high antibody titres and 100% seroconversion also resulted from treble, and especially quadruple primary intramuscular immunization using a dose of 1.5 ml on days 0, 8, 16, 24 or 0, 8, 16 and 32. When treating bites of non-dangerous localization, CPCRV can be administered in a dose of 1.5 ml at a time on days 0, 7 15, 30 and 60 (5 injections in total). The scheme of combined vaccinations using CPCRV and antirabies gamma-globulin requires exploration.

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D011818 Rabies Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf. Encephalitic Rabies,Furious Rabies,Hydrophobia,Paralytic Rabies,Lyssa,Furious Raby,Lyssas,Rabies, Encephalitic,Rabies, Furious,Raby, Furious
D011819 Rabies Vaccines Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. Rabies Human Diploid Cell Vaccine,Rabies Vaccine,Vaccine, Rabies,Vaccines, Rabies
D011820 Rabies virus The type species of LYSSAVIRUS causing rabies in humans and other animals. Transmission is mostly by animal bites through saliva. The virus is neurotropic multiplying in neurons and myotubes of vertebrates. Rabies viruses
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
Immunogenic and antigenic activity of an experimental oral rabies vaccine prepared from the strain Vnukovo-32/107.
March 1995, Veterinarni medicina,
M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
[Oral immunization of Arctic foxes with a live rabies tissue-culture vaccine from the Vnukovo-32 strain].
January 1987, Voprosy virusologii,
M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
Quantification of residual virulence of the Vnukovo-32/107 rabies virus vaccination strain.
February 1995, Veterinarni medicina,
M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
[Specific activity of a concentrated, chromatography-purified cultured rabies vaccine].
February 1988, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
Specific activity of tissue culture antirabic vaccine Rabivak-Vnukovo-32 with short intramuscular vaccination schedule.
May 1988, Acta virologica,
M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
Evaluation of the inactivated tissue culture rabies vaccine from the Vnukovo-32 strain. Results of its industrial production and field use for post-exposure immunization of man.
January 1978, Developments in biological standardization,
M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
Development of an edible rabies vaccine in maize using the Vnukovo strain.
January 2008, Developments in biologicals,
M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
[Study of the interfering activity of the Vnukovo-32 vaccinal strain of the rabies virus].
January 1973, Voprosy virusologii,
M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin.
July 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
M Selimov, and L El'bert, and T Aksenova, and E Klyueva, and L Gribencha, and A Movsesyants, and L Antonova, and I Kamenetskaya, and N Mishchenko, and L Krupenin, and M Bugayeva, and V Yaretskaya, and A Pyaeva
Nucleotide and deduced amino acid sequences of the glycoprotein gene of rabies virus vaccine strain Vnukovo-32.
January 1994, Archives of virology,
Copied contents to your clipboard!